Anterior chamber proliferative membrane interception (AC-PMI)-enhanced trabeculectomy versus trabeculectomy for treating neovascular glaucoma: protocol for a randomized controlled trial

MLA

Shuqing Zhu, et al. “Anterior Chamber Proliferative Membrane Interception (AC-PMI)-Enhanced Trabeculectomy versus Trabeculectomy for Treating Neovascular Glaucoma: Protocol for a Randomized Controlled Trial.” Trials, vol. 25, no. 1, Apr. 2024, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s13063-024-08123-8.

APA

Shuqing Zhu, Mengtian Zhou, Haoyu Li, Shaodan Zhang, Shuxia Xu, Haishuang Lin, Yanqie Xie, Rongrong Le, & Yuanbo Liang. (2024). Anterior chamber proliferative membrane interception (AC-PMI)-enhanced trabeculectomy versus trabeculectomy for treating neovascular glaucoma: protocol for a randomized controlled trial. Trials, 25(1), 1–8. https://doi.org/10.1186/s13063-024-08123-8

Chicago

Shuqing Zhu, Mengtian Zhou, Haoyu Li, Shaodan Zhang, Shuxia Xu, Haishuang Lin, Yanqie Xie, Rongrong Le, and Yuanbo Liang. 2024. “Anterior Chamber Proliferative Membrane Interception (AC-PMI)-Enhanced Trabeculectomy versus Trabeculectomy for Treating Neovascular Glaucoma: Protocol for a Randomized Controlled Trial.” Trials 25 (1): 1–8. doi:10.1186/s13063-024-08123-8.